HRP20090345T1 - Pegylated liposomal doxorubicin in combination with ecteinescidin 743 - Google Patents
Pegylated liposomal doxorubicin in combination with ecteinescidin 743Info
- Publication number
- HRP20090345T1 HRP20090345T1 HR20090345T HRP20090345T HRP20090345T1 HR P20090345 T1 HRP20090345 T1 HR P20090345T1 HR 20090345 T HR20090345 T HR 20090345T HR P20090345 T HRP20090345 T HR P20090345T HR P20090345 T1 HRP20090345 T1 HR P20090345T1
- Authority
- HR
- Croatia
- Prior art keywords
- combination
- ecteinescidin
- pegylated liposomal
- liposomal doxorubicin
- therapeutic amount
- Prior art date
Links
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940045799 anthracyclines and related substance Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62216304P | 2004-10-26 | 2004-10-26 | |
| PCT/GB2005/050189 WO2006046080A2 (en) | 2004-10-26 | 2005-10-26 | Pegylated liposomal doxorubicin in combination with ecteinescidin 743 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20090345T1 true HRP20090345T1 (en) | 2009-08-31 |
Family
ID=36096124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20090345T HRP20090345T1 (en) | 2004-10-26 | 2009-06-15 | Pegylated liposomal doxorubicin in combination with ecteinescidin 743 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20090117176A1 (da) |
| EP (1) | EP1827500B1 (da) |
| JP (2) | JP4554684B2 (da) |
| KR (1) | KR101287918B1 (da) |
| CN (1) | CN101119750B (da) |
| AT (1) | ATE430586T1 (da) |
| AU (1) | AU2005298364B2 (da) |
| BR (1) | BRPI0518250A2 (da) |
| CA (1) | CA2582452C (da) |
| CY (1) | CY1110329T1 (da) |
| DE (1) | DE602005014380D1 (da) |
| DK (1) | DK1827500T3 (da) |
| ES (1) | ES2326825T3 (da) |
| HK (1) | HK1107766A1 (da) |
| HR (1) | HRP20090345T1 (da) |
| IL (1) | IL182352A (da) |
| MX (1) | MX2007004744A (da) |
| NO (1) | NO328958B1 (da) |
| NZ (1) | NZ554765A (da) |
| PL (1) | PL1827500T3 (da) |
| PT (1) | PT1827500E (da) |
| RS (1) | RS50822B (da) |
| RU (1) | RU2359700C2 (da) |
| SI (1) | SI1827500T1 (da) |
| UA (1) | UA87877C2 (da) |
| WO (1) | WO2006046080A2 (da) |
| ZA (1) | ZA200703396B (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY164077A (en) | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| MXPA02011319A (es) | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| NZ525730A (en) * | 2000-11-06 | 2004-12-24 | Pharma Mar S | Compositions for antitumour treatments containing Ecteinascidin 743 |
| GB0117402D0 (en) * | 2001-07-17 | 2001-09-05 | Pharma Mar Sa | New antitumoral derivatives of et-743 |
| GB0202544D0 (en) | 2002-02-04 | 2002-03-20 | Pharma Mar Sa | The synthesis of naturally occuring ecteinascidins and related compounds |
| PT1689404E (pt) | 2003-11-13 | 2008-12-15 | Pharma Mar Sau | Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro |
| AU2004291037A1 (en) * | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer |
| PL1658848T3 (pl) | 2004-10-29 | 2007-12-31 | Pharma Mar Sa | Preparaty zawierające ekteinascydynę i disacharyd |
| GB0522082D0 (en) | 2005-10-31 | 2005-12-07 | Pharma Mar Sa | Formulations |
| US8444963B2 (en) | 2006-06-19 | 2013-05-21 | John Hopkins University | Tumor specific delivery of therapeutic agents via liposomase |
| US20100267732A1 (en) * | 2007-10-19 | 2010-10-21 | Pharma Mar, S.A. | Prognostic Molecular Markers for ET-743 Treatment |
| KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
| JOP20190254A1 (ar) | 2017-04-27 | 2019-10-27 | Pharma Mar Sa | مركبات مضادة للأورام |
| RU2657835C1 (ru) * | 2017-11-28 | 2018-06-15 | Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский технологический университет "МИСиС" | Способ получения системы для доставки противоопухолевого препарата в клетки опухоли |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256663A (en) * | 1986-06-09 | 1993-10-26 | The Board Of Trustees Of The University Of Illinois | Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith |
| US5149804A (en) * | 1990-11-30 | 1992-09-22 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins 736 and 722 |
| US5089273A (en) * | 1986-06-09 | 1992-02-18 | Board Of Trustees Of The University Of Illinois | Ecteinascidins 729, 743, 745, 759A, 759B and 770 |
| DE3635711A1 (de) * | 1986-10-21 | 1988-04-28 | Knoll Ag | 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung |
| US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| FR2697752B1 (fr) * | 1992-11-10 | 1995-04-14 | Rhone Poulenc Rorer Sa | Compositions antitumorales contenant des dérivés du taxane. |
| US5478932A (en) * | 1993-12-02 | 1995-12-26 | The Board Of Trustees Of The University Of Illinois | Ecteinascidins |
| US20040059112A1 (en) * | 1994-02-18 | 2004-03-25 | Rinehart Kenneth L. | Ecteinascidins |
| GB9508195D0 (en) * | 1995-04-20 | 1995-06-07 | Univ British Columbia | Novel biologically active compounds and compositions,their use and derivation |
| US5721362A (en) * | 1996-09-18 | 1998-02-24 | President And Fellows Of Harvard College | Process for producing ecteinascidin compounds |
| US5985876A (en) * | 1997-04-15 | 1999-11-16 | Univ Illinois | Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
| CA2327468C (en) * | 1998-04-06 | 2008-05-06 | The Board Of Trustees Of The University Of Illinois | Semi-synthetic ecteinascidins |
| US6124292A (en) * | 1998-09-30 | 2000-09-26 | President And Fellows Of Harvard College | Synthetic analogs of ecteinascidin-743 |
| MY164077A (en) * | 1999-05-13 | 2017-11-30 | Pharma Mar Sa | Compositions and uses of et743 for treating cancer |
| MY130271A (en) * | 1999-05-14 | 2007-06-29 | Pharma Mar Sa | Hemisynthetic method and new compounds |
| US20020028237A1 (en) * | 2000-04-20 | 2002-03-07 | Colbern Gail T. | Method for reducing toxicity of a cytotoxic agent |
| US7247892B2 (en) * | 2000-04-24 | 2007-07-24 | Taylor Geoff W | Imaging array utilizing thyristor-based pixel elements |
| US7420051B2 (en) * | 2000-05-15 | 2008-09-02 | Pharma Mar, S.A. | Synthetic process for the manufacture of an ecteinaschidin compound |
| MXPA02011319A (es) * | 2000-05-15 | 2003-06-06 | Pharma Mar Sa | Analogos antitumorales de ecteinascidina 743. |
| EP1356097A2 (en) * | 2000-08-11 | 2003-10-29 | City of Hope | The anti-neoplastic agent et-743 inhibits trans activation by sxr |
| ATE314084T1 (de) * | 2000-10-31 | 2006-01-15 | Pharma Mar Sa | Kahalalid f formulierung |
| NZ525730A (en) * | 2000-11-06 | 2004-12-24 | Pharma Mar S | Compositions for antitumour treatments containing Ecteinascidin 743 |
| WO2002076459A1 (en) * | 2001-03-06 | 2002-10-03 | Bristol-Myers Squibb Company | Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin |
| EP1401396A4 (en) * | 2001-06-15 | 2009-08-05 | Cornerstone Pharmaceuticals | PHARMACEUTICAL AND DIAGNOSTIC COMPOSITIONS WITH NANOPARTICLES FOR THE TREATMENT OF TARGET TISSUE AND CELLS |
| BR0213424A (pt) * | 2001-10-19 | 2004-12-14 | Pharma Mar Sa | Uso aperfeiçoado de composto antitumoral na terapia contra câncer |
| US20040019027A1 (en) * | 2002-04-12 | 2004-01-29 | Barry Forman | Method of treating cerebrotendinous xanthomatosis |
| US20040082856A1 (en) * | 2002-07-16 | 2004-04-29 | Alfred E. Mann Institute For Biomedical Engineering, University Of Southern California | Support bra for ultrasonic breast scanner |
| GB0312407D0 (en) * | 2003-05-29 | 2003-07-02 | Pharma Mar Sau | Treatment |
| GB0324201D0 (en) * | 2003-10-15 | 2003-11-19 | Pharma Mar Sau | Improved antitumoral combinations |
| PT1689404E (pt) * | 2003-11-13 | 2008-12-15 | Pharma Mar Sau | Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro |
| AU2004291037A1 (en) * | 2003-11-14 | 2005-06-02 | Pharma Mar, S.A. | Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer |
| GB0326486D0 (en) * | 2003-11-14 | 2003-12-17 | Pharma Mar Sau | Combination treatment |
| US20050129752A1 (en) * | 2003-12-15 | 2005-06-16 | Tty Biopharm Limited Company | Use and manufacturing process for liposomal doxorubicin pharmaceutical composition |
| EP1768671A2 (en) * | 2004-07-09 | 2007-04-04 | Pharma Mar, S.A. | Use of ecteinascidin in the treatment of cancer in patients with low level of brca1 |
| PL1658848T3 (pl) * | 2004-10-29 | 2007-12-31 | Pharma Mar Sa | Preparaty zawierające ekteinascydynę i disacharyd |
| WO2007062413A2 (en) * | 2005-11-25 | 2007-05-31 | University Of Medicine And Dentistry Of New Jersey | Use of parp-1 inhibitors |
| US20080075772A1 (en) * | 2006-04-13 | 2008-03-27 | Lawrence Solomon | Pharmaceutical compositions having novel scoring patterns and methods of using those compositions |
| JP2009536956A (ja) * | 2006-05-12 | 2009-10-22 | ファルマ・マール・ソシエダード・アノニマ | 抗癌治療法 |
-
2005
- 2005-10-26 CN CN2005800369316A patent/CN101119750B/zh active Active
- 2005-10-26 JP JP2007538524A patent/JP4554684B2/ja active Active
- 2005-10-26 NZ NZ554765A patent/NZ554765A/en unknown
- 2005-10-26 BR BRPI0518250-6A patent/BRPI0518250A2/pt not_active Application Discontinuation
- 2005-10-26 PL PL05803151T patent/PL1827500T3/pl unknown
- 2005-10-26 UA UAA200705818A patent/UA87877C2/ru unknown
- 2005-10-26 RU RU2007119545/14A patent/RU2359700C2/ru active
- 2005-10-26 DE DE602005014380T patent/DE602005014380D1/de active Active
- 2005-10-26 WO PCT/GB2005/050189 patent/WO2006046080A2/en active Application Filing
- 2005-10-26 EP EP05803151A patent/EP1827500B1/en not_active Revoked
- 2005-10-26 AT AT05803151T patent/ATE430586T1/de active
- 2005-10-26 MX MX2007004744A patent/MX2007004744A/es active IP Right Grant
- 2005-10-26 AU AU2005298364A patent/AU2005298364B2/en active Active
- 2005-10-26 ES ES05803151T patent/ES2326825T3/es active Active
- 2005-10-26 PT PT05803151T patent/PT1827500E/pt unknown
- 2005-10-26 DK DK05803151T patent/DK1827500T3/da active
- 2005-10-26 KR KR1020077009355A patent/KR101287918B1/ko active IP Right Grant
- 2005-10-26 CA CA2582452A patent/CA2582452C/en active Active
- 2005-10-26 US US11/577,790 patent/US20090117176A1/en not_active Abandoned
- 2005-10-26 RS RSP-2009/0311A patent/RS50822B/sr unknown
- 2005-10-26 SI SI200530688T patent/SI1827500T1/sl unknown
-
2007
- 2007-04-01 IL IL182352A patent/IL182352A/en active IP Right Grant
- 2007-04-25 ZA ZA200703396A patent/ZA200703396B/xx unknown
- 2007-05-16 NO NO20072543A patent/NO328958B1/no unknown
-
2008
- 2008-01-22 HK HK08100804.8A patent/HK1107766A1/xx unknown
-
2009
- 2009-06-15 HR HR20090345T patent/HRP20090345T1/xx unknown
- 2009-08-03 CY CY20091100818T patent/CY1110329T1/el unknown
- 2009-09-24 JP JP2009219607A patent/JP2009292850A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1107766A1 (en) | Pegylated liposomal doxorubicin in combination with ecteinescidin 743 | |
| WO2004103301A3 (en) | Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents | |
| WO2001066123A3 (en) | Composition consisting of phy906 and chemotherapeutic agents | |
| EP1262179A4 (en) | PHOTODYNAMIC THERAPY FOR SELECTIVELY TREATING NEOVAISSEAUX IN THE BOTTOM OF THE EYE TISSUE | |
| AU2001282717A1 (en) | Cancer treatment by combination therapy | |
| AU2001297644A1 (en) | B/b-like fragment targeting for the purposes of photodynamic therapy and medical imaging | |
| WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
| WO2005037323A3 (en) | Use of gro to treat or prevent inflammation | |
| EP1435988A4 (en) | IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER | |
| TW200633700A (en) | Methods of using temozolomide formulation intrathecally in the treatment of cancers | |
| EP1605847A4 (en) | PHOTODYNAMIC THERAPY PROVIDED AGAINST ANTIBODIES | |
| HUP0400153A2 (en) | Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment | |
| IL141550A0 (en) | Methods and compositions for the prevention or treatment of cancer | |
| GB0020504D0 (en) | Therapeutic method | |
| AU4789099A (en) | Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents | |
| MXPA04005207A (es) | Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos. | |
| WO2006069217A3 (en) | Small molecule cyclin d1 ablative agents | |
| AU2002325721A1 (en) | Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer | |
| AU2003287834A1 (en) | Use of aglycon protopanaxadiol in cancer therapy | |
| AU2003287833A1 (en) | Use of aglycon protopanaxatriol in cancer therapy | |
| WO2003059334A3 (en) | Gemcitabine in the treatment of smallpox | |
| GB0022216D0 (en) | Human FAP-a-specific antibodies for use in cancer therapy | |
| AUPR227100A0 (en) | Composition for use in the treatment of patients with kidney stones | |
| AU2002313087A1 (en) | Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment | |
| AU2001236911A1 (en) | Lipophilin complexes for use in cancer diagnosis and therapy |